| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Papers |
Gastrointestinal Cancer Clinic, Massachusetts General Hospital Cancer Center, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA
Correspondence: David P. Ryan, M.D., MGH Cancer Center, Cox 6, 100 Blossom Street, Boston, Massachusetts 02114, USA. Telephone: 617-726-8515; Fax: 617-724-3166; e-mail: ryan.david{at}mgh.harvard.edu
The cure rate for pancreatic cancer remains less than 5% despite more than 20 years of clinical trials. Nevertheless, a select group of patients benefit from therapy at all stages of disease and important concepts regarding patient care have emerged. The development of agents such as gemcitabine and docetaxel have spurred a new generation of clinical trials in pancreatic cancer. An appreciation for the results of the many adjuvant and neoadjuvant trials and the application of lessons learned in the care of these patients is necessary to design the new trials.
This article has been cited by other articles:
![]() |
A. Vonlaufen, S. Joshi, C. Qu, P. A. Phillips, Z. Xu, N. R. Parker, C. S. Toi, R. C. Pirola, J. S. Wilson, D. Goldstein, et al. Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells Cancer Res., April 1, 2008; 68(7): 2085 - 2093. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. El Kamar, M. L. Grossbard, and P. S. Kozuch Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care Oncologist, February 1, 2003; 8(1): 18 - 34. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |